ML347
Based on 10 publication(s) in Google Scholar
ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC50 values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 1062368-49-3
- Formula: C22H16N4O
- Molecular Weight:352.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ML347
More- Bone Res. 2024 Sep 4;12(1):50. [Abstract]
- J Cell Mol Med. 2024 Nov;28(22):e70214. [Abstract]
- Biomedicines. 2026 Jan 28;14(2):288. [Abstract]
- J Leukoc Biol. 2023 Nov 24;114(6):639-650. [Abstract]
- J Mol Histol. 2021 Feb;52(1):77-86. [Abstract]
- Oncologie. 2025 Mar 4.
- SSRN. 2025 Jul 25.
- Patent. US20220002732A1.
- J Bioma Ter Tiss Eng. 2020 Jun.
- Patent. US20170369886A1.
-
WB
Biological Activity
Description
IC50 & Target
[1]|
ALK1 46 nM (IC50) |
ACVR1 32 nM (IC50) |
BMPR1A 10800 nM (IC50) |
In Vitro
ML347 can inhibit ALK1/ALK2 to block TGF?β signal transduction[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Primary dental epithelial cells were cultured in Dulbecco’s Modifed Eagle Medium (DMEM)/ F12 supplemented with 20% fetal bovine serum and 1% penicillin/streptomycin.
-
Concentration:25 μM
-
Incubation Time:2 hours
-
Result:Inhibited ALK1/ALK2 then blocking Smad1/5 by TGF-β1.
Chemical Information
-
CAS No. 1062368-49-3
-
Appearance Solid
-
Molecular Weight 352.39
-
Formula C22H16N4O
-
Color Light yellow to yellow
-
SMILES
COC1=CC=C(C2=CN3C(N=C2)=C(C4=C5C=CC=NC5=CC=C4)C=N3)C=C1
-
Synonyms
LDN 193719
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Bone Res
Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development. [Abstract]2024 Sep 4;12(1):50. PMID: 39231936 -
J Cell Mol Med
Sinomenine Ameliorated Microglial Activation and Neuropathic Pain After Chronic Constriction Injury Via TGF-β1/ALK5/Smad3 Signalling Pathway. [Abstract]2024 Nov;28(22):e70214. PMID: 39586784 -
Biomedicines
2026 Jan 28;14(2):288. PMID: 41751187 -
J Leukoc Biol
Non-functional TGF-β/ALK1/ENG Signaling Pathway supports neutrophil pro-angiogenic activity in Hereditary Hemorrhagic Telangiectasia. [Abstract]2023 Nov 24;114(6):639-650. PMID: 37555392 -
J Mol Histol
2021 Feb;52(1):77-86. PMID: 33206256 -
-
-
-
-
ML347 purchased from MedChemExpress. Usage Cited in: Patent. US20170369886A1.
FIG illustrates angiogenesis in the absence and presence of an Alk1 small molecule inhibitor (ML347) in presence or absence of inhibin α.
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (28.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
-
Handling Instructions (2659 KB)
References
[1]. Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. [Content Brief]
[2]. Zhang H, et al. Dual roles of TGF-β signaling in the regulation of dental epithelial cell proliferation. J Mol Histol. 2021 Feb;52(1):77-86. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8378 mL | 14.1888 mL | 28.3776 mL | 70.9441 mL |
| 5 mM | 0.5676 mL | 2.8378 mL | 5.6755 mL | 14.1888 mL | |
| 10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL | 7.0944 mL | |
| 15 mM | 0.1892 mL | 0.9459 mL | 1.8918 mL | 4.7296 mL | |
| 20 mM | 0.1419 mL | 0.7094 mL | 1.4189 mL | 3.5472 mL | |
| 25 mM | 0.1135 mL | 0.5676 mL | 1.1351 mL | 2.8378 mL |